nach oben

Wiener klinische Wochenschrift

21.01.2025 | letter to the editors

Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma

A retrospective single center experience

verfasst von: Muhammad Safwan, Ishwa Shakir, Saman Naz

Erschienen in: Wiener klinische Wochenschrift

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Müller C, Bergmann M, Stift A, Bachleitner-Hofmann T, Riss S. Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma. Wien Klin Wochenschr. 2024; https://doi.org/10.1007/s00508-024-02460-z.CrossRefPubMedPubMedCentral

Yaşar S, Yılmaz F, Utkan G, Algın E, Bayram D, Tamam S, Öksüzoğlu ÖB, İlhan A, Erdat EC, Ünal AE, Yalçın Ş. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024; https://doi.org/10.1245/s10434-024-15506-3.CrossRefPubMedPubMedCentral

Graham I, Boston A, Hayward R, Berri R. Outcomes following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies: 10 year experience. Am J Surg. 2024;230:78–81. https://doi.org/10.1016/j.amjsurg.2024.01.031.CrossRefPubMed

Steadman JA, Grotz TE. Principles of surgical management of peritoneal mesothelioma. J Natl Compr Cancer Netw. 2023;21(9):981–6. https://doi.org/10.6004/jnccn.2023.7055.CrossRef

Shamavonian R, Cheng E, Karpes JB, Barat S, Ahmadi N, Morris DL. Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: outcomes and survival from an Australian centre. Anticancer Res. 2022;42(6):2939–44. https://doi.org/10.21873/anticanres.15776.CrossRefPubMed

Hotza G, Karageorgos M, Pastourmatzi V, Baniowda N, Kyziridis D, Kalakonas A, Chavouzis N, Hotza I, Tentes AA. Morbidity and mortality of patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Discov Oncol. 2024;15(1):106. https://doi.org/10.1007/s12672-024-00968-4.CrossRefPubMedPubMedCentral

Ravn S, Grønfeldt JM, Thaysen HV, Iversen LH. The impact of the extent of surgery on late adverse effects following cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2024;50(1):107105–107101. https://doi.org/10.1007/s12672-024-00968-4.CrossRefPubMed

Titel: Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma
A retrospective single center experience
verfasst von: Muhammad Safwan
Ishwa Shakir
Saman Naz
Publikationsdatum: 21.01.2025
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-024-02493-4

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten